|Daily Range||$30.92 - $31.37|
|52-Week Range||$30.85 - $38.54|
|Dividend (Yield)||$0.00 (2.7%)|
|Average Daily Volume||1,398,964|
|Current FY EPS||$1.80|
The launch of trials in dry age-related macular degeneration failed to spark shares last month.
Learn more about healthcare technologies and trends such as these -- and you will discover some intriguing investment possibilities
Celgene outperformed the broader market in 2015, but can the company deliver superior results once more in 2016?
What might be in store in 2016 for this up-and-coming biotech.
Celgene's presentation at the Super Bowl of all healthcare conferences on Monday unearthed plenty of must-know information for investors.
Exelixis stock surged 291% in 2015, and it has these two events to thank for the rapid rise.
2015 was horrible for this biotech. Here's what could be on tap in the New Year.
Four drugs made a huge impact on patient survival in 2015 according to clinical trials, and one of them can be bought over the counter.
The company is sticking to plans to file for FDA approval of neratinib in the first quarter of 2016.
Clinical trial results will be coming out next year that could significantly move the shares in these stocks higher or lower.